Skip to main content
SpringerLink
Log in

Botulinum Toxin Treatment in Multiple Sclerosis

  • Chapter
  • First Online:
Botulinum Toxin Treatment in Clinical Medicine

Abstract

Multiple sclerosis is a common disease in which the disease process involves multiple levels of the central nervous system leading to the emergence of a myriad of clinical symptoms. The symptomatic treatment of multiple sclerosis often does not meet patient’s satisfaction despite the availability of a variety of pharmacotherapeutic agents. This evidence-based review discusses the utility of botulinum neurotoxin therapy for treating the symptoms of multipe sclerosis. The available data from randomized, blinded clinical trials indicate that BoNT therapy is efficacious for the treatment of spasticity, bladder dysfunction, and certain types of focal pain in multiple sclerosis. Emerging literature from open-label observations suggests the utility of BoNT therapy in several other symptoms caused by MS: certain tremors, myokymia, tonic spasms, spastic dysphagia, and internuclear ophthalmoplegia. The data on MS-related sialorrhea are not available.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  1. Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016;86:1014–21.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care. 2011;17(Suppl 5 Improving):S139–45.

    PubMed  Google Scholar 

  3. Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16:639–47.

    Article  PubMed  Google Scholar 

  4. Compston A, Wekerle H, McDonald I. The origin of multiple sclerosis: a synthesis. In: Compston A, editor. McAlpine’s multiple sclerosis. 4th ed. New York: Churchill Livingstone; 2006. p. 273–84.

    Chapter  Google Scholar 

  5. Diebold M, Derfuss T. Immunological treatment of multiple sclerosis. Semin Hematol. 2016;53(Suppl 1):S54–7.

    Article  PubMed  Google Scholar 

  6. Moeini-Naghani I, Hashemi-Zonouz T, Jabbari B. Botulinum toxin treatment of spasticity in adults and children. Semin Neurol. 2016;36:64–72.

    Article  PubMed  Google Scholar 

  7. Lance JW. The control of muscle tone, reflexes, and movement: Robert Wartenberg lecture. Neurology. 1980;30:1303–13.

    Article  CAS  PubMed  Google Scholar 

  8. Gracies JM. Pathophysiology of spastic paresis. I: paresis and soft tissue changes. Muscle Nerve. 2005;31(5):535–51.

    Article  PubMed  Google Scholar 

  9. Gracies JM. Pathophysiology of spastic paresis. II: emergence of muscle over activity. Muscle Nerve. 2005;31(5):552–71.

    Article  PubMed  Google Scholar 

  10. Gioux M, Petit J. Effects of immobilizing the cat peroneus longus muscle on the activity of its own spindles. J Appl Physiol (1985). 1993;31(5):552–71.

    Google Scholar 

  11. Crone C, Johnsen LL, Biering-Srensen F, Nielsen JB. Appearance of reciprocal facilitation of ankle extensors from ankle flexors in patients with stroke or spinal cord injury. Brain. 2003;126(pt 2):495–507.

    Article  CAS  PubMed  Google Scholar 

  12. Kheder A, Nair KPS. Spasticity: pathophysiology, evaluation and management, practical. Neurology. 2012;12:289.

    Google Scholar 

  13. Yelnik AP, Simon O, paratte B, et al. How to clinically assess and treat muscle overactivity in spastic paresis. J Rehabil Med. 2010;42:801–7.

    Article  PubMed  Google Scholar 

  14. Pozzilli C. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Rev Neurother. 2013;13(12 Suppl):49–54.

    Article  PubMed  Google Scholar 

  15. Rizzo MA, Hadjimichael OC, preingerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10:589–95.

    Article  CAS  PubMed  Google Scholar 

  16. Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther. 2009;26(12):1043–57.

    Article  PubMed  Google Scholar 

  17. Martin A, Abogunrin S, Kurth H, Dinet J. Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic review. Neuropsychiatr Dis Treat. 2014;10:111–22.

    PubMed  PubMed Central  Google Scholar 

  18. Flachenecker P, Henze T, Zettl UK. Spasticity in patients with multiple sclerosis—clinical characteristics, treatment and quality of life. Acta Neurol Scand. 2014;129(3):154–62.

    Article  CAS  PubMed  Google Scholar 

  19. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol. 1990;28:512–5.

    Article  CAS  PubMed  Google Scholar 

  20. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology. 1995;45:712–7.

    Article  CAS  PubMed  Google Scholar 

  21. Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, Poewe W, Wissel J, Bain P, Glickman S, Sayer A, Richardson A, Dott C. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000;68:707–12.

    Google Scholar 

  22. Phadke CP, Davidson C, Ismail F, Boulias C. The effect of neural lesion type on botulinum toxin dosage: a retrospective chart review. PM R. 2014;6:406–11.

    Article  PubMed  Google Scholar 

  23. Schramm A, Ndayisaba JP, Auf dem Brinke M, Hecht M, Herrmann C, Huber M, Lobsien E, Mehnert S, Reuter I, Stenner A, van der Ven C, Winterholler M, Kupsch A, Wissel J. Spasticity treatment with onabotulinumtoxin A: data from a prospective German real-life patient registry. J Neural Transm (Vienna). 2014;121:521–30.

    Google Scholar 

  24. Nuanthaisong U, Abraham N, Goldman HB. Incidence of adverse events after high doses of onabotulinumtoxinA for multiple indications. Urology. 2014;84:1044–8.

    Article  PubMed  Google Scholar 

  25. Foley PL, Vesterinen HM, Laird BJ, Sena ES, Colvin LA, Chandran S, Mac Leod MR, Fallon M. Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis. Pain 2013;154:632–42.

    Google Scholar 

  26. Truini A, Barbanti P, Pozzilli C, Cruccu G. A mechanism-based classification of pain in multiple sclerosis. J Neurol. 2013;260:351–67.

    Article  CAS  PubMed  Google Scholar 

  27. Nurmikko TJ, Gupta S, Maclver K. Multiple sclerosis-related central pain disorders. Curr Pain Headache rep. 2010;14:189–95.

    Article  PubMed  Google Scholar 

  28. Al-Araji AH, Oger J. Reappraisal of Lhermitte’s sign in multiple sclerosis. Mult Scler. 2005;11:398–402.

    Article  PubMed  Google Scholar 

  29. Mueller D, Obermann M, Yoon MS, et al. Prevalence of trigeminal neuralgia and persistent idiopathic facial pain: a population-based study. Cephalalgia. 2011;31:1542–8.

    Article  PubMed  Google Scholar 

  30. Broggi G, et al. Operative findings and outcomes of microvascular decompression for trigeminal neuralgia in 35 patients affected by multiple sclerosis. Neurosurgery. 2004;55:830–8. discussion 838–9

    Article  PubMed  Google Scholar 

  31. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology. 1991;10:276–81.

    Article  CAS  PubMed  Google Scholar 

  32. Cruccu G, Finnerup NB, Jensen TS, Scholz J, Sindou M, Svensson P, Treede RD, Zakrzewska JM, Nurmikko T. Trigeminal neuralgia: new classification and diagnostic grading for practice and research. Neurology. 2016;87:220–8.

    Google Scholar 

  33. Cruccu G, Gronseth G, Alksne J, et al. AANEFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15:1013–28.

    Article  CAS  PubMed  Google Scholar 

  34. Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, Kent JL, Krane EJ, Lebel AA, Levy RM, Mackey SC, Mayer J, Miaskowski C, Raja SN, Rice AS, Schmader KE, Stacey B, Stanos S, Treede RD, Turk DC, Walco GA, Wells CD. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85 (3 Suppl):S3–14.

    Google Scholar 

  35. Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 2007;120(16):2864–74.

    Article  CAS  PubMed  Google Scholar 

  36. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125–33.

    Article  CAS  PubMed  Google Scholar 

  37. Shin MC, Wakita M, Xie DJ, et al. Inhibition of membrane Na+ channels by a type botulinum toxin at femtomolar concentrations in central and peripheral neurons. J Pharmacol Sci. 2012;118:33–42.

    Article  CAS  PubMed  Google Scholar 

  38. Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D. Subcutaneous injection of Botulinum toxin A is beneficial in postherpetic neuralgia. Pain Med. 2010;11:1827–33.

    Article  PubMed  Google Scholar 

  39. Ranoux DA, Attal N, Morain F, Bouhassira D. Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64:274–83.

    Article  PubMed  Google Scholar 

  40. Yuan RY, Sheu JJ, YuJ M, Chen WT, Tseng IJ, Chang HH, Hu CJ. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial Neurology. 2009;72: 1473–8.

    Google Scholar 

  41. Wu CJ, Lian YJ, Zheng YK, et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012;32:443–50.

    Article  Google Scholar 

  42. Shehata HS, El-Tamawy MS, Shalaby NM, Ramzy G. Botulinum toxin-type A: could it be n effective treatment option in intractable trigeminal neuralgia? J Headache Pain. 2013;14:92.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Zuniga C, Piedimonte F, Diaz S, Micheli F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin Neuropharmacol. 2013;36:146–50.

    Article  CAS  PubMed  Google Scholar 

  44. Zhang H, Lian Y, Ma Y, et al. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo- controlled trial. J Headache Pain. 2014;15:65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Shaikh A, Phadke CP, Ismail F, Boulias C. Relationship between Botulinum toxin, spasticity, and pain: a survey of patient perception. Can J Neurol Sci. 2016;43:311–5.

    Article  PubMed  Google Scholar 

  46. Marco E, Duarte E, Vila J, Tejero M, Guillen A, Boza R, Escalada F, Espadaler JM. Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. Rehabil Med. 2007;39: 440–7.

    Google Scholar 

  47. Shaw LC, Price CI, van Wijck FM, Shackley P, Steen N, Barnes MP, Ford GA, Graham LA, Rodgers H; BoTULS Investigators. Botulinum toxin for the upper limb after stroke (BoTULS) trial: effect on impairment, activity limitation, and pain. Stroke. 2011;42:1371–9.

    Google Scholar 

  48. Rosales RL, Kong KH, Goh KJ, Kumthornthip W, Mok VC, Delgado-De Los Santos MM, Chua KS, Abdullah SJ, Zakine B, Maisonobe P, Magis A, Wong KS. Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial. Neurorehabil Neural Repair. 2012;26: 812–21.

    Google Scholar 

  49. Moisset X, Ouchchane L, Guy N, Bayle DJ, Dallel R, Clavelou P. Migraine headaches and pain with neuropathic characteristics: comorbid conditions in patients with multiple sclerosis. Pain. 2013;154:2691–9.

    Article  PubMed  Google Scholar 

  50. Gelfand AA, Gelfand JM, Goadsby PJ. Migraine and multiple sclerosis: epidemiology and approach to treatment. Mult Scler Relat Disord. 2013;2:73–9.

    Article  PubMed  Google Scholar 

  51. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010; 50:921–36.

    Google Scholar 

  52. Shibasaki H, Kuroiwa Y. Painful tonic seizures in multiple sclerosis. Arch Neurol. 1974;30:47–51.

    Article  CAS  PubMed  Google Scholar 

  53. Restivo DA, Tinazzi M, Patti F, Palmeri A, Maimone D. Botulinum toxin treatment of painful tonic spasms in multiple sclerosis. Neurology. 2003;61:719–20.

    Article  CAS  PubMed  Google Scholar 

  54. Yonnet GJ, Fjeldstad AS, Carlson NG, Rose JW. Advances in the management of neurogenic detrusor overactivity in multiple sclerosis. Int J MS Case. 2013;15:66–72.

    Article  Google Scholar 

  55. Holstege G. Descending motor pathways and spinal motor system.: limbic and non-limbic components. Prog Brain Res. 1991;87:307–421.

    Article  CAS  PubMed  Google Scholar 

  56. Griffiths D. Neural control of micturition in humans: a working model. Nat Rev Urol. 2015;12:695–705.

    Article  CAS  PubMed  Google Scholar 

  57. Ruffion A, Castro-Diaz D, Patel H, Khalaf K, Onyenwenyi A, Globe D, et al. Systematic review of the epidemiology of urinary incontinence and detrusor overactivity among patients with neurogenic overactive bladder. Neuroepidemiology. 2013;41:146–55.

    Article  PubMed  Google Scholar 

  58. Mahajan ST, Patel PB, Marrie RA. Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. J Urol. 2010;183:1432–7.

    Article  CAS  PubMed  Google Scholar 

  59. Wintner A, Kim MM, Bechis SK, Kreydin EI. Voiding dysfunction in multiple sclerosis. Semin Neurol. 2016;36:34–40.

    Article  PubMed  Google Scholar 

  60. de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B, GENULF. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007;13:915–28.

    Article  PubMed  Google Scholar 

  61. Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009;80:470–7.

    CAS  PubMed  Google Scholar 

  62. Carpenter FG. Motor responses of the urinary bladder and skeletal muscle in botulinum intoxicated rats. J Physiol. 1967;188:1–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Schurch B, Hauri D, Largo M, Kreienbühl B, Meyer E, Rossier AB. Effects of Botulinum a toxin on the periurethral striated sphincter of the neurogenic bladder. Preliminary study. 63. J Urol (Paris). 1990;96:375–80.

    CAS  Google Scholar 

  64. Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil. 1990;71:24–6.

    CAS  PubMed  Google Scholar 

  65. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60: 742–50.

    Google Scholar 

  66. Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, Brin MF, Jenkins B, Haag-Molkenteller C. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187:2131–9.

    Google Scholar 

  67. Cruz F, Nitti V. Chapter 5: clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). Neurourol Urodyn. 2014;33(Suppl 3):S26–31.

    Article  PubMed  Google Scholar 

  68. Smith CP, Chancellor MB. Botulinum toxin to treat neurogenic bladder. Semin Neurol. 2016;36:5–9.

    Article  PubMed  Google Scholar 

  69. Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, Plante P, Perrouin-Verbe B, Kumar C, Fraczek S, Brin MF; Botox Detrusor Hyperreflexia Study Team. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005; 174:196–200.

    Google Scholar 

  70. Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, Bard R, Valiquette L, Baverstock R, Carr L, Radomski S. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185:2229–35.

    Google Scholar 

  71. Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32:242–9.

    Article  CAS  PubMed  Google Scholar 

  72. Denys P, Del Popolo G, Amarenco G, Karsenty G, Le Berre P, Padrazzi B, Picaut P; Dysport Study Group. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): a randomised placebo-controlled phase IIa study. Neurourol Urodyn. 2016; 36(2):457–62. [Epub ahead of print].

    Google Scholar 

  73. Gallien P, Reymann JM, Amarenco G, Nicolas B, de Sèze M, Bellissant E. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005;76:1670–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Meador W, Salter AR, Rinker JR II. Symptomatic management of multiple sclerosis-associated tremor among participants in the NARCOMS registry. Int J MS Care. 2016;18:147–53.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Koch M, Mostert J, Heersema D, et al. Tremor in multiple sclerosis. J Neurol. 2007;254:133–45.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Koller WC. Pharmacologic trials in the treatment of cerebellar tremor. Arch Neurol. 1984;41:280–1.

    Article  CAS  PubMed  Google Scholar 

  77. Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996;11:250–6.

    Article  CAS  PubMed  Google Scholar 

  78. Rahimi F, Bee C, Debicki D, Roberts AC, Bapat P, Jog M. Effectiveness of BoNT A in Parkinson’s disease upper limb tremor management. Can J Neurol Sci. 2013;40:663–9.

    Article  PubMed  Google Scholar 

  79. Rostami R, Chow C, Richardson D, Jabbari B, Machado D. Botulinum toxin treatment of essential tremor—a customized approach—AAN—poster S27-002, AAN meeting, April 18, 2016.

    Google Scholar 

  80. Mittal OS, Rostami R, Machado D, Richardson D, Jabbari B. A double blind investigation of efficacy and safety of incobotulinumtoxinA in Parkinson disease tremor—a customized injection approach. Abstract # 1896. Platform presentation S40-007, AAN meeting April 18, 2016.

    Google Scholar 

  81. Clarke CE. Botulinum toxin type A in cerebellar tremor caused by multiple sclerosis. Eur J Neurol. 1997;4:68–71.

    Article  CAS  PubMed  Google Scholar 

  82. Gutmann L, Gutmann L. Myokymia and neuromyotonia. J Neurol. 2004;251:138–42.

    Article  PubMed  Google Scholar 

  83. Andermann F, Cosgrove JBR, Lloyd-Smith DL, Gloor P, McNaughton FL. Facial myokymia in multiple sclerosis. Brain. 1961;84:31–44.

    Article  Google Scholar 

  84. Jacobs L, Kaba S, Pullicino P. The lesion causing continuous facial myokymia in multiple sclerosis. Arch Neurol. 1994;51:1115–9.

    Article  CAS  PubMed  Google Scholar 

  85. Sedano MJ, Trejo JM, Macarrón JL, Polo JM, Berciano J, Calleja J. Continuous facial myokymia in multiple sclerosis: treatment with botulinum toxin. Eur Neurol. 2000;43:137–40.

    Article  CAS  PubMed  Google Scholar 

  86. Gutmann L, Brick JF, Riggs JE. Calcium and myokymia of brainstem origin. Neurology. 1986;36:26–30.

    Google Scholar 

  87. Habek M, Adamec I, Gabelić T, Brinar VV. Treatment of facial myokymia in multiple sclerosis with botulinum toxin. Acta Neurol Belg. 2012;112:423–4.

    Article  PubMed  Google Scholar 

  88. Restivo DA, Marchese-Ragona R, Patti F, Solaro C, Maimone D, Zappalá G, Pavone A. Botulinum toxin improves dysphagia associated with multiple sclerosis. Eur J Neurol. 2011;18:486–90.

    Google Scholar 

  89. Murthy R, Dawson E, Khan S, Adams GG, Lee J. Botulinum toxin in the management of internuclear ophthalmoplegia. J AAPOS. 2007;11:456–9.

    Article  PubMed  Google Scholar 

  90. Hosp C, Naumann MK, Hamm H. Botulinum toxin treatment of autonomic disorders: focal hyperhidrosis and Sialorrhea. Semin Neurol. 2016;36:20–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Scholar, Division of Nephrology and Hypertention, University of California, Irvine, USA

    Yasaman Safarpour M.D.

  2. Department of Neurology, Yale University School of Medicine, New Haven, CT, USA

    Bahman Jabbari M.D., FAAN

  3. 31 Silver Pine Drive, Newport Coast, CA, 92657, USA

    Bahman Jabbari M.D., FAAN

Authors
  1. Yasaman Safarpour M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bahman Jabbari M.D., FAAN
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bahman Jabbari M.D., FAAN .

Editor information

Editors and Affiliations

  1. Emeritus Professor of Neurology, Yale University, New Haven, Connecticut, USA

    Bahman Jabbari

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Safarpour, Y., Jabbari, B. (2018). Botulinum Toxin Treatment in Multiple Sclerosis. In: Jabbari, B. (eds) Botulinum Toxin Treatment in Clinical Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-56038-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56038-0_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56037-3

  • Online ISBN: 978-3-319-56038-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation